Sign in
Taking people in United StatesEarly phase 1

Compares two metformin doses in young people with type 2 diabetes

Compares a usual metformin dose with a higher dose in youth with type 2 diabetes.

Key facts

Who runs it
University of California, San Francisco
Where
Oakland and San Francisco, United StatesSee the 2 sites
Trial code
Registry title
Precision Dosing of Metformin in Youth With T2D
Status
Recruiting
Phase
Early phase 1
People taking part
20 people, planned
Started
25 Apr 2024
Expected to end
31 Dec 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Metformin
Record updated
23 December 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for young people aged 10-21 years with type 2 diabetes who already take regular metformin. It compares the usual metformin dose with a higher dose.

Age
10-21 years
Sex
All sexes can join.
Disease stage
Type 2 diabetes diagnosed by a provider at least 1 month ago.
Earlier treatment
Taking regular metformin (not extended-release) and a stable medication regimen for 2 weeks before screening, with no more than 20% change in insulin dose.
Biomarker or test result
No pancreatic autoantibodies (GAD-65, insulin, IA-2, ICA 512, Zn-T8).

Main reasons for not taking part

  • Positive pancreatic autoantibodies (GAD-65, insulin, IA-2, ICA 512, Zn-T8)
  • Known ongoing kidney or liver disease
  • Significant mental illness or developmental delay that stops you doing study activities on your own

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Age 10-21 years
  • Provider diagnosis of T2D
  • Stable medication regimen for 2 weeks before screening visit (No addition or removal of medications and no more than 20% change in insulin dose)
  • ≥ 1 month from T2D diagnosis
  • Taking regular metformin (not extended-release formula)
  • Ability to wear CGM for a total of 6 weeks while in the study
  • English or Spanish speakers
  • Willing to abide by recommendations and study procedures
  • Willing and able to sign the Informed Consent Form (ICF) and/or has a parent or guardian willing and able to sign the ICF
  • Participant and parent(s)/guardian(s) willingness to participate in all training sessions as directed by study staff. Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study

Who cannot take part

  • Known history of ongoing renal or hepatic disease
  • Known history of significant mental illness or developmental delay impacting the ability to complete study activities independently
  • Pancreatic autoantibody positivity (GAD-65, insulin, IA-2, ICA 512, Zn-T8)

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 10 and 21 years old?

Where in United States

  • UCSF Benioff Children's Hospital Oakland, Pediatric Diabetes ClinicOakland, United StatesContact: Shylaja Srinivasan, MDTaking people
  • UCSF Benioff Children's Hospital San Francisco, Madison Clinic for Pediatric DiabetesSan Francisco, United StatesContact: Shylaja A Srinivasan, MDTaking people

About the trial

What the trial wants to find out

The purpose of this study to compare the typically prescribed dose of metformin (1000mg twice a day) with a higher dose of metformin (1350mg twice a day).

The 2 groups in the trial

  • ExperimentalTreatment being tested

    1350mg metformin twice per day

    Treatment: Metformin

  • Active ComparatorExisting treatment, for comparison

    1000mg metformin twice per day

    Treatment: Metformin

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Pilot Study of Precision Dosing of Metformin in Youth With Type 2 Diabetes (PRECISE_T2D)
Plain-language title
Compares two metformin doses in young people with type 2 diabetesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06120881, who can take part
Record updated
23 December 2025